PetCaseFinder

Peer-reviewed veterinary case report

Outcomes for 18 dogs treated for malignant ovarian tumors

By Goto, Sho et al.·Published in Veterinary and comparative oncology·2021·Gifu University, Japan·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: A retrospective analysis on the outcome of 18 dogs with malignant ovarian tumours.

Species:
dog
Canine mammary tumorsBehaviour & energyDogs

Plain-English summary

An older female dog with a malignant ovarian tumor was treated with surgery, and some dogs also received chemotherapy or radiotherapy. The study looked at 18 dogs, mostly around 12 years old, and found that those with early-stage tumors had a better chance of survival. On average, dogs lived about 1009 days after treatment, but those without metastasis (spread of cancer) lived significantly longer. The results suggest that aggressive treatment can be beneficial, even for dogs with advanced disease, as many survived over a year despite having metastasis at diagnosis.

People also search for: dog ovarian tumor treatment · malignant ovarian tumor prognosis in dogs · dog cancer survival rates

Abstract

Little evidence is available regarding the prognosis of dogs with malignant ovarian tumours. The objective of this retrospective study was to describe the outcomes and determine the prognostic factors for dogs with malignant ovarian tumours following treatment, including surgery with or without adjuvant therapy. Eighteen dogs were studied, their median age was 12&#x2009;years (range: 7-15&#x2009;years), and their median body weight was 6.9&#xa0;kg (range: 2.3-17.8&#xa0;kg). Following histopathologic diagnoses revealed that granulosa cell tumour was the most common type (n&#xa0;=&#xa0;9), followed by dysgerminoma (n&#xa0;=&#xa0;5), and adenocarcinoma (n&#xa0;=&#xa0;4). Eleven dogs had surgery alone. Seven dogs had surgery with adjuvant therapy, including chemotherapy and/or radiotherapy. The median survival time (ST) was 1009&#x2009;days when only deaths owing to the ovarian tumours were considered, and predictors of median ST were T-category (&#x2265;&#xa0;T3, 443&#x2009;days vs&#xa0;&#x2264;&#xa0;T2, 1474&#x2009;days; P&#xa0;=&#xa0;.002), presence of metastatic disease (present, 391&#x2009;days vs absent, 1474&#x2009;days; P&#x2009;<&#x2009;.001) and lymphovascular space invasion (present, 428&#x2009;days vs absent, 1474&#x2009;days; P&#xa0;=&#xa0;.003) in a univariate analysis. Median ST in dogs with granulosa cell tumour seemed longer than in dogs with dysgerminoma and adenocarcinoma, although the difference was statistically insignificant (1474&#x2009;days vs 458&#x2009;days, respectively; P&#xa0;=&#xa0;.10). Considering the good prognosis, aggressive treatment can be recommended for dogs with malignant ovarian tumours, especially early-stage cases. Despite metastasis being present at diagnosis, half of the dogs with metastasis survived for more than 1&#x2009;year.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32700381/